Results 11 to 20 of about 35,228 (288)

Applications of patient-derived tumor xenograft models and tumor organoids [PDF]

Journal of Hematology & Oncology, 2020
Patient-derived tumor xenografts (PDXs), in which tumor fragments surgically dissected from cancer patients are directly transplanted into immunodeficient mice, have emerged as a useful model for translational research aimed at facilitating precision ...
Go J. Yoshida
doaj   +3 more sources

Patient-derived tumor organoids for prediction of cancer treatment response

Seminars in Cancer Biology, 2018
Cancer treatment, in particular radiotherapy and chemotherapy, is often hindered by an inherent resistance of cancer cells. Cancer stem cells in particular have previously been shown to be more resistant than other cells within a tumor and are thought repopulate the tumour after therapies.
Peter W. Nagle, John Th. M. Plukker, Christina T. Muijs, Peter van Luijk, Robert P. Coppes   +4 more
exaly   +5 more sources

Cost-reduction strategy to culture patient derived bladder tumor organoids

Scientific Reports
Organoids as self-organized structure derived from stem cells can recapitulate the function of an organ in miniature form which have developed great potential for clinical translation, drug screening and personalized medicine.
Mahsa Mollapour Sisakht, Fatemeh Gholizadeh, Shirin Hekmatirad, Tokameh Mahmoudi, Saeed Montazeri, Laleh Sharifi, Hamed Daemi, Shahla Romal, Mohammad Hosein Yazdi, Mohammad Ali Faramarzi, Ahmad Reza Shahverdi, Amir Ali Hamidieh   +11 more
doaj   +3 more sources

Grouped-seq for integrated phenotypic and transcriptomic screening of patient-derived tumor organoids. [PDF]

Nucleic Acids Res, 2022
Abstract Patient-derived tumor organoids (PDOs) have emerged as a reliable in vitro model for drug discovery. However, RNA sequencing-based analysis of PDOs treated with drugs has not been realized in a high-throughput format due to the limited quantity of organoids. Here, we translated a newly developed pooled RNA-seq methodology onto a
Wu Y, Li K, Li Y, Sun T, Liu C, Dong C, Zhao T, Tang D, Chen X, Chen X, Liu P.   +10 more
europepmc   +6 more sources

Patient‐ and xenograft‐derived organoids recapitulate pediatric brain tumor features and patient treatments

EMBO Molecular Medicine, 2023
Brain tumors are the leading cause of cancer‐related death in children. Experimental in vitro models that faithfully capture the hallmarks and tumor heterogeneity of pediatric brain cancers are limited and hard to establish.
Chiara Lago, Aniello Federico, Gloria Leva, Norman L Mack, Benjamin Schwalm, Claudio Ballabio, Matteo Gianesello, Luana Abballe, Isabella Giovannoni, Sofia Reddel, Sabrina Rossi, Nicolas Leone, Andrea Carai, Angela Mastronuzzi, Alessandra Bisio, Alessia Soldano, Concetta Quintarelli, Franco Locatelli, Marcel Kool, Evelina Miele, Luca Tiberi   +20 more
doaj   +2 more sources

High-resolution positron emission microscopy of patient-derived tumor organoids. [PDF]

Nat Commun, 2021
AbstractOrganoid tumor models have found application in a growing array of cancer studies due to their ability to closely recapitulate the structural and functional characteristics of solid tumors. However, organoids are too small to be compatible with common radiological tools used in oncology clinics.
Khan S, Shin JH, Ferri V, Cheng N, Noel JE, Kuo C, Sunwoo JB, Pratx G.   +7 more
europepmc   +6 more sources

Patient-derived tumor organoids as a platform of precision treatment for malignant brain tumors. [PDF]

Sci Rep, 2022
AbstractMalignant brain tumors consist of malignancies originated primarily within the brain and the metastatic lesions disseminated from other organs. In spite of intensive studies, malignant brain tumors remain to be a medical challenge. Patient-derived organoid (PDO) can recapitulate the biological features of the primary tumor it was derived from ...
Chen CC, Li HW, Wang YL, Lee CC, Shen YC, Hsieh CY, Lin HL, Chen XX, Cho DY, Hsieh CL, Guo JH, Wei ST, Wang J, Wang SC.   +13 more
europepmc   +4 more sources

Preclinical testing of oncolytic adenovirus sensitivity in patient-derived tumor organoids. [PDF]

STAR Protoc, 2021
Patient-derived organoids (PDOs) have shown the potential to reflect patient sensitivity to chemotherapeutic or targeted drugs. Recently, we showed that organoid models can also serve as a platform to screen for selectivity and potency of oncolytic adenoviruses (OAds).
Pascual-Sabater S, Raimondi G, Mato-Berciano A, Vaquero EC, Ausania F, Fillat C.   +5 more
europepmc   +4 more sources

Patient-derived tumor organoids: A preclinical platform for personalized cancer therapy. [PDF]

Transl Oncol
Patient-derived tumor organoids (PDTOs) represent a significant advancement in cancer research and personalized medicine. These organoids, derived from various cancer types, have shown the ability to retain the genetic and molecular characteristics of the original tumors, allowing for the detailed study of tumor biology and drug responses on an ...
Taurin S, Alzahrani R, Aloraibi S, Ashi L, Alharmi R, Hassani N.   +5 more
europepmc   +4 more sources

Patient-derived tumor organoids to model drug response in gastric cancer. [PDF]

Cell Rep Med
Gastric cancer poses diverse treatment challenges due to its high tumor heterogeneity. Through the use of patient-derived tumor organoid (PDO) models, new research1 has identified genes and molecular signatures that are predictive of chemotherapeutic response, providing valuable insights for clinical management and translational advancements.
Vistoso Monreal A, Zhao H, Sedghizadeh PP, Lin DC.   +3 more
europepmc   +3 more sources